Our discovery of CD38 and CD39 expression on the surface of cytotoxic tumor-specific CD4+ T cells will allow the identification and isolation of this cell type for future studies and clinical trials relating to CD4+ T-cell specific immunotherapies. The gene discussed is ENTPD1; the disease is neoplasm.